Stephane Bancel Net Worth (Updated 2025).

Stephane Bancel, a French-American businessman, launched his career in the biotechnology industry after earning his MBA from the prestigious Harvard Business School. He started his professional journey at Eli Lilly and Company, where he gained valuable experience in the pharmaceutical sector.

In 2010, Bancel co-founded Moderna, a biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. His innovative approach to mRNA technology, which involves using genetic instructions to trigger a patient’s cells to produce their own vaccines or therapies, catapulted him into the limelight.

Stephane Bancel’s Current Net Worth (2025)

As of 2025, Stephane Bancel’s estimated net worth is $4.5 billion. This significant wealth is largely attributed to his successful career in the biotechnology industry and his role as the CEO of Moderna, a leading biotech company known for its mRNA vaccines.

Career

Stephane Bancel is a French businessman and the current CEO of Moderna, a position he has held since 2010. He played a pivotal role in transforming Moderna from a research-stage company into a commercial-stage company, successfully leading it through its initial public offering (IPO) in 2018.

Other Ventures

Prior to joining Moderna, Bancel served as a vice president at biotech giant Genzyme. He also co-founded a biotech company called BioAlliance Pharma, which was later acquired by SORALAB. Currently, he serves on the board of directors of the Biotechnology Innovation Organization (BIO).

Assets

Bancel’s assets include a significant stake in Moderna, estimated to be around 10% of the company’s shares. He also owns a luxurious home in the Boston area, valued at approximately $5 million. Additionally, he has invested in various other biotech and healthcare companies, diversifying his portfolio.

Annual Income

As of 2021, Stephane Bancel’s base salary was $1.5 million, with additional compensation including stock awards and non-equity incentive plan compensation totaling over $28 million. His total compensation for 2021 was approximately $30 million, reflecting his crucial role in leading Moderna.

Frequently Asked Questions about  Stephane Bancel

Frequently Asked Questions: Stephane Bancel Net Worth

1. What is Stephane Bancel’s net worth?

Stephane Bancel’s net worth is estimated to be around $4.5 billion.

2. How did Stephane Bancel make his fortune?

Stephane Bancel made his fortune as the CEO of Moderna, a biotechnology company that specializes in developing mRNA vaccines and therapies. He co-founded the company in 2010 and has been serving as its CEO since then.

3. What is Stephane Bancel’s role at Moderna?

Stephane Bancel is the current CEO of Moderna, a position he has held since the company’s inception in 2010. He is responsible for the overall vision and strategic direction of the company.

4. What is Stephane Bancel’s educational background?

Stephane Bancel holds a Master of Science degree in Engineering from the École Spéciale des Travaux Publics, a graduate engineering school in Paris, France. He also has an MBA from the Harvard Business School.

5. What is Stephane Bancel’s nationality?

Stephane Bancel is French. He was born in France and holds French citizenship.

6. When was Stephane Bancel born?

Stephane Bancel was born on April 14, 1972.

7. What is Stephane Bancel’s salary at Moderna?

According to SEC filings, Stephane Bancel’s total compensation at Moderna in 2021 was $58.4 million, which includes his salary, stock awards, and other forms of compensation.

8. What is Stephane Bancel’s stake in Moderna?

As of 2021, Stephane Bancel owned approximately 9% of Moderna’s outstanding shares, making him one of the company’s largest shareholders.

9. What is Stephane Bancel’s philanthropic work?

Stephane Bancel is known for his philanthropic work, particularly in the area of global health. He has been a vocal advocate for improving access to vaccines in low- and middle-income countries.

10. What are Stephane Bancel’s future plans for Moderna?

Stephane Bancel has stated that Moderna’s future plans include expanding its mRNA technology to treat a wide range of diseases, including cancer, rare diseases, and infectious diseases. The company is also working on developing vaccines for emerging infectious diseases and boosting the immune response to seasonal influenza.